Information Provided By: 
Fly News Breaks for March 22, 2019
EW, NVCN
Mar 22, 2019 | 08:27 EDT
Canaccord analyst Jason Mills said the ruling yesterday from a German court in dismissing the claim to co-inventorship of the Tiara device made by Edwards Lifesciences' (EW) CardiAQ removes a litigation overhang for Neovasc (NVCN). Mills continues to view Neovasc as an "attractive, albeit admittedly risky," play on the Transcatheter Mitral Valve Repair sector and keeps a Buy rating and $1.10 price target on the shares.
News For NVCN;EW From the Last 2 Days
There are no results for your query NVCN;EW
